Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations

Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations is a phase 3, randomised interventional study registered as NCT05445791 by Instituto Nacional de Cancerologia de Mexico, with a registry enrolment figure of 312 participants, started 2021-07-15 and due to reach its primary completion in 2026-07-14. Interventions recorded: Metformin Hydrochloride; Placebo. Conditions listed: Non Small Cell Lung Cancer. Primary outcome: Progression-free survival. Lung eligibility wording from the registry: "Patients with a histologically confirmed diagnosis of non-small cell lung cancer (stage IIIB-IV) according to the American Joint Committee on Cancer (AJCC) eight edition". Sites: Mexico. No results are recorded here; the registry entry is the source.